211 related articles for article (PubMed ID: 17159604)
1. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.
Gazzaniga P; Silvestri I; Gradilone A; Scarpa S; Morrone S; Gandini O; Gianni W; Frati L; Aglianò AM
Anticancer Drugs; 2007 Feb; 18(2):179-85. PubMed ID: 17159604
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
[TBL] [Abstract][Full Text] [Related]
3. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Gunelli R; Bercovich E; Nanni O; Ballardini M; Frassineti GL; Giovannini N; Fiori M; Pasquini E; Ulivi P; Pappagallo GL; Silvestrini R; Zoli W
Br J Cancer; 2007 Dec; 97(11):1499-504. PubMed ID: 17987035
[TBL] [Abstract][Full Text] [Related]
4. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
Kurdow R; Schniewind B; Zoefelt S; Boenicke L; Boehle AS; Dohrmann P; Kalthoff H
Langenbecks Arch Surg; 2005 Jun; 390(3):243-8. PubMed ID: 15726400
[TBL] [Abstract][Full Text] [Related]
6. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
7. Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL.
Moibi JA; Mak AL; Sun B; Moore RB
Int J Oncol; 2011 Jul; 39(1):61-71. PubMed ID: 21537842
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
11. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H
Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
14. [Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].
Liu A; Hu YS; Wang ZH; Tang LL; Ke PY; Lin SZ
Yao Xue Xue Bao; 2011 Feb; 46(2):146-52. PubMed ID: 21542284
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
Papadopoulos EI; Yousef GM; Scorilas A
Tumour Biol; 2015 May; 36(5):3197-207. PubMed ID: 25833690
[TBL] [Abstract][Full Text] [Related]
16. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
17. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer.
Gazzaniga P; Gradilone A; Giuliani L; Gandini O; Silvestri I; Nofroni I; Saccani G; Frati L; Aglianò AM
Ann Oncol; 2003 Jan; 14(1):85-90. PubMed ID: 12488298
[TBL] [Abstract][Full Text] [Related]
18. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
19. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]